Literature DB >> 20370587

Micromarkers: miRNAs in cancer diagnosis and prognosis.

Manuela Ferracin1, Angelo Veronese, Massimo Negrini.   

Abstract

Molecular diagnostics in cancer should provide the highest specificity and sensitivity in classification, prognostic stratification and early detection. miRNAs could contribute to hitting the mark, or at least to come nearer, by virtue of their cancer-specific expression and stability. Indeed, different to other RNA classes, miRNAs can be detected and quantified not only in frozen tissues, but also in formalin-fixed paraffin-embedded tissues, as well as serum/plasma samples. Thus, miRNA studies have quickly moved from research on the molecular basis of cancer to areas of clinical application. This review summarizes the potential role of miRNAs as molecular markers for cancer classification, prognostic stratification and drug-response prediction. It also summarizes their potential as circulating markers and cancer-predisposing genes. If we consider that studies on miRNAs in cancer therapy have already given important contributions, miRNAs have an impact in all cancer areas. Whether this will translate into clinical applications is still too early to say. However, in the diagnostic field, miRNAs may already represent an improvement over presently available approaches; for example, their expression profile is effective in the identification of tissue of origin of metastasis. In addition, circulating miRNAs are expected to provide improved specificity and/or sensitivity over presently available markers.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20370587     DOI: 10.1586/erm.10.11

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  111 in total

1.  MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.

Authors:  Xiao He; Xia Xiao; Lin Dong; Nengbin Wan; Zhengyu Zhou; Hongwu Deng; Xiefu Zhang
Journal:  Tumour Biol       Date:  2014-11-15

2.  MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.

Authors:  Manuela Ferracin; Massimo Pedriali; Angelo Veronese; Barbara Zagatti; Roberta Gafà; Eros Magri; Maria Lunardi; Gardenia Munerato; Giulia Querzoli; Iva Maestri; Linda Ulazzi; Italo Nenci; Carlo M Croce; Giovanni Lanza; Patrizia Querzoli; Massimo Negrini
Journal:  J Pathol       Date:  2011-06-01       Impact factor: 7.996

3.  A high-throughput screen identifies miRNA inhibitors regulating lung cancer cell survival and response to paclitaxel.

Authors:  Liqin Du; Robert Borkowski; Zhenze Zhao; Xiuye Ma; Xiaojie Yu; Xian-Jin Xie; Alexander Pertsemlidis
Journal:  RNA Biol       Date:  2013-09-30       Impact factor: 4.652

4.  MiR-16 family as potential diagnostic biomarkers for cancer: a systematic review and meta-analysis.

Authors:  Jianxiong Cui
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Prognostic value of circulating microRNA-21 in digestive system cancers: a meta-analysis.

Authors:  Ting-Ting Ye; Yin-Long Yang; Xin-Ying Liu; Qian-Qing Ji; Yi-Fei Pan; You-Qun Xiang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

6.  Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.

Authors:  Fulya Yaman Agaoglu; Müge Kovancilar; Yavuz Dizdar; Emin Darendeliler; Stefan Holdenrieder; Nejat Dalay; Ugur Gezer
Journal:  Tumour Biol       Date:  2011-01-28

7.  Development of a Low-Cost Stem-Loop Real-Time Quantification PCR Technique for EBV miRNA Expression Analysis.

Authors:  Massimiliano Bergallo; Chiara Merlino; Davide Montin; Ilaria Galliano; Stefano Gambarino; Katia Mareschi; Franca Fagioli; Paola Montanari; Silvana Martino; Pier-Angelo Tovo
Journal:  Mol Biotechnol       Date:  2016-09       Impact factor: 2.695

8.  Diagnostic performance of microRNAs expression in prostate cancer.

Authors:  Qinfeng Yang; Yushan Zheng; Dequan Zhu
Journal:  Tumour Biol       Date:  2014-07-25

9.  Defining Plasma MicroRNAs Associated With Cognitive Impairment In HIV-Infected Patients.

Authors:  Ferdous Kadri; Andrea LaPlante; Mariacristina De Luca; Lisa Doyle; Cruz Velasco-Gonzalez; Jonathan R Patterson; Patricia E Molina; Steve Nelson; Arnold H Zea; Christopher H Parsons; Francesca Peruzzi
Journal:  J Cell Physiol       Date:  2016-04       Impact factor: 6.384

10.  MicroRNA gene dosage alterations and drug response in lung cancer.

Authors:  Katey S S Enfield; Greg L Stewart; Larissa A Pikor; Carlos E Alvarez; Stephen Lam; Wan L Lam; Raj Chari
Journal:  J Biomed Biotechnol       Date:  2011-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.